26/12/2025
Tirzepatide: Use and Indications in Diabetes & Obesity
Tirzepatide is a novel injectable medication that acts as a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. This dual mechanism provides superior glycemic control and significant weight reduction compared to traditional GLP-1 receptor agonists.
⸻
1. Indications
A. Type 2 Diabetes Mellitus (T2DM)
Approved indication
Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes Mellitus.
Clinical benefits:
• Significant reduction in HbA1c (up to 2.0–2.5%)
• Improves fasting and post-prandial glucose
• Promotes weight loss, beneficial in overweight/obese diabetics
• Low risk of hypoglycemia when used without insulin or sulfonylureas
Use in therapy:
• Can be used as monotherapy or add-on therapy with:
• Metformin
• SGLT2 inhibitors
• Basal insulin (dose adjustment needed)
⸻
B. Obesity / Overweight
Approved indication (in many countries)
Indicated for chronic weight management in adults with:
• BMI ≥30 kg/m² (Obesity)
OR
• BMI ≥27 kg/m² (Overweight) with at least one weight-related comorbidity:
• Type 2 diabetes
• Hypertension
• Dyslipidemia
• Obstructive sleep apnea
Benefits:
• Average 15–22% body weight reduction
• Improves cardiometabolic risk factors
• Reduces insulin resistance
⸻
2. Mechanism of Action
Tirzepatide works by:
• Enhancing glucose-dependent insulin secretion
• Suppressing glucagon release
• Delaying gastric emptying
• Reducing appetite and caloric intake
The dual GIP + GLP-1 action leads to better glycemic control and greater weight loss than GLP-1 agonists alone.
⸻
3. Dosage & Administration
• Route: Subcutaneous injection
• Frequency: Once weekly
• Starting dose: 2.5 mg weekly (for tolerance, not glycemic control)
• Titration: Increase every 4 weeks
• Maintenance doses: 5 mg, 10 mg, or 15 mg weekly
⸻
4. Common Side Effects
Mostly gastrointestinal and dose-dependent:
• Nausea
• Vomiting
• Diarrhea
• Constipation
• Reduced appetite
These usually improve with gradual dose escalation.
⸻
5. Contraindications & Precautions
Contraindicated in:
• Personal or family history of medullary thyroid carcinoma
• MEN type 2
• Known hypersensitivity
Use with caution in:
• Severe GI disease (e.g., gastroparesis)
• Patients on insulin or sulfonylureas (risk of hypoglycemia)
• History of pancreatitis (relative contraindication)
⸻
6. Advantages Over Other Agents
• Greater HbA1c reduction
• Superior weight loss
• Once-weekly dosing
• Cardiometabolic benefits
Summary:
Feature
Tirzepatide
Drug Class
Dual GIP & GLP-1 receptor agonist
Indications
Type 2 Diabetes, Obesity
Weight Loss
Very high (15–22%)
HbA1c Reduction
Up to 2.5%
Dosing
Weekly SC injection
Note: All medicines should only be used with a proper doctor’s prescription and clear medical indication. Self-medication can be harmful to health
